In contrast, other studies that developed PopPK models of adalimumab in Crohn’s disease [19,21] or IBD patients [22] observed that higher albumin levels were associated with lower adalimumab CL/F and higher serum levels, considering albumin as an influential inflammatory marker of adalimumab clearance, although, finally, they did not include it as a covariate in the PopPK model. This evidence concerns the gene ALB and Crohn disease.